Extracellular vesicle small RNA cargo discriminates non-cancer donors from pediatric B-lymphoblastic leukemia patients

Front Oncol. 2023 Nov 13:13:1272883. doi: 10.3389/fonc.2023.1272883. eCollection 2023.

Abstract

Pediatric B-acute lymphoblastic leukemia (B-ALL) is a disease of abnormally growing B lymphoblasts. Here we hypothesized that extracellular vesicles (EVs), which are nanosized particles released by all cells (including cancer cells), could be used to monitor B-ALL severity and progression by sampling plasma instead of bone marrow. EVs are especially attractive as they are present throughout the circulation regardless of the location of the originating cell. First, we used nanoparticle tracking analysis to compare EVs between non-cancer donor (NCD) and B-ALL blood plasma; we found that B-ALL plasma contains more EVs than NCD plasma. We then isolated EVs from NCD and pediatric B-ALL peripheral blood plasma using a synthetic peptide-based isolation technique (Vn96), which is clinically amenable and isolates a broad spectrum of EVs. RNA-seq analysis of small RNAs contained within the isolated EVs revealed a signature of differentially packaged and exclusively packaged RNAs that distinguish NCD from B-ALL. The plasma EVs contain a heterogenous mixture of miRNAs and fragments of long non-coding RNA (lncRNA) and messenger RNA (mRNA). Transcripts packaged in B-ALL EVs include those involved in negative cell cycle regulation, potentially suggesting that B-ALL cells may use EVs to discard gene sequences that control growth. In contrast, NCD EVs carry sequences representative of multiple organs, including brain, muscle, and epithelial cells. This signature could potentially be used to monitor B-ALL disease burden in pediatric B-ALL patients via blood draws instead of invasive bone marrow aspirates.

Keywords: B-ALL; extracellular vesicles; gene signature; leukemia; small non-coding RNA.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by funds from the Janeway Children’s Hospital Foundation to SLC and PM for PROFYLE. J-AH was supported by a Janeway Foundation Trainee Award. ML was supported by a Memorial University of Newfoundland and Labrador School of Graduate Studies fellowship; and a Cancer Research Training Program (CRTP) studentship award from the Beatrice Hunter Cancer Research Institute through GIVETOLIVE.